• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ampio gains investigational drug nod for COVID-19 inhaler

September 28, 2020 By Danielle Kirsh

ampioAmpio recently announced that it received FDA investigational new drug designation to proceed with clinical trials of its Ampion inhaler for patients with COVID-19 respiratory distress.

The company is expanding on its recent successful Phase I trial that administered the drug intravenously to COVID-19 patients. The new Phase I trial of inhaled Ampion will total 40 patients and assess the safety and efficacy of the inhaled drug as a standard of care for COVID-19 infected patients that are hospitalized due to respiratory distress.

Ampion will be administered through a handheld nebulizer and inhaled to allow the drug to directly target and attenuate inflammation in the lungs, according to the company. The clinical trial will study the effects of inhaled Ampion while emphasizing early intervention treatment throughout the progression of COVID-19.

Toxicology studies of the drug have demonstrated that Amption is safe for inhalation and has effectively reduced signaling proteins responsible for tissue damage and pulmonary complications.

Filed Under: Pharmaceuticals Tagged With: Ampio Pharmaceutical, coronavirus, COVID-19

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS